Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000697496 | SCV000826111 | uncertain significance | Brugada syndrome 4 | 2018-01-16 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 349 of the CACNB2 protein (p.Val349Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs752546853, ExAC 0.002%). This variant has not been reported in the literature in individuals with CACNB2-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000697496 | SCV002813435 | uncertain significance | Brugada syndrome 4 | 2021-10-18 | criteria provided, single submitter | clinical testing |